Printer Friendly

QUADRA LOGIC RECEIVES CANADIAN MARKETING CLEARANCE FOR PHOTODYNAMIC THERAPY (PDT) AS NEW CANCER TREATMENT

PHOTOFRIN (R) is the First Light-Activated Drug Approved for PDT
 VANCOUVER, British Columbia, April 20 /PRNewswire/ -- Quadra Logic Technologies Inc. (Vancouver: QLT) has received regulatory clearance from the Health Protection Branch in Canada to market the light-activated drug PHOTOFRIN(R) as a treatment for recurrent superficial papillary bladder cancer.
 "Canada is the first country in the world to authorize the marketing of Photodynamic Therapy (PDT) with PHOTOFRIN as a new form of treatment for cancer," says William J. Foran, president and chief executive officer of QLT.
 "PHOTOFRIN is the first light-activated drug to receive marketing approval anywhere in the world. It establishes Photodynamic Therapy as a new modality of cancer treatment that can now begin to take its place beside radiation, surgery and chemotherapy."
 "As a Canadian company, we are very proud to have achieved our initial marketing clearance in Canada -- the country where the first regulatory submissions for PDT with PHOTOFRIN were filed," Foran says.
 The marketing clearance granted allows physicians to use PDT with PHOTOFRIN to treat patients with recurrent superficial papillary bladder cancer who have failed other forms of therapy. This is an important approval for PHOTOFRIN because the use of PDT for the prevention of further superficial bladder cancer recurrences will spare the patient repeated surgical removal of tumours under general anesthetic.
 Data submitted for review included a multicenter clinical trial conducted in the United States where results showed that one course of PDT with PHOTOFRIN can significantly delay the recurrence of superficial papillary bladder cancer.
 Data from this trial showed that patients receiving a single intrabladder treatment with PHOTOFRIN had only a 45 percent recurrence rate, while 83 percent of those patients who did not receive PDT developed new tumor growth. Patients receiving PDT with PHOTOFRIN had a median delayed time to recurrence of 394 days vs. 90 days for patients in the control group not undergoing any treatment.
 "Although Canada represents less than 5 percent of our total potential market and Canadian sales of PHOTOFRIN for this application will not make Quadra Logic profitable -- marketing approval in Canada is an important first step," Foran says.
 "Our business strategy is to build on this approval and achieve approvals for the drug in selected countries throughout the world."
 Regulatory submissions seeking marketing approval of PDT with PHOTOFRIN for the treatment of lung, bladder and esophageal cancers have been filed in seven European countries and Japan. The Japanese submission is for early-stage cancers of the lung, bladder, esophagus, stomach and cervix.
 In Canada, additional licensing applications of PHOTOFRIN -- which were submitted along with the superficial papillary bladder cancer indication -- have not been granted marketing clearance at this time. These additional indications will be dealt with through the normal process of Supplemental New Drug Submission application.
 "The PHOTOFRIN approval in Canada underscores the pioneering role that Quadra Logic has played in the development of new drugs and applications for Photodynamic Therapy," says Dr. Julia Levy, senior vice president and chief scientific officer at Quadra Logic.
 "The approval of PHOTOFRIN is a major milestone for all of us in the Canadian biopharmaceutical field," Levy adds.
 More than 5,000 cases of bladder cancer are diagnosed annually in Canada, of which approximately 75 percent are considered superficial papillary bladder cancer. Medical lasers of the type necessary to treat bladder cancer with PHOTOFRIN are presently located at seven major Canadian hospitals and cancer clinics.
 Photodynamic Therapy with PHOTOFRIN is a two-step process. The drug is first injected intravenously into the patient's body. This is followed by an interval during which the drug circulates, accumulates and is retained in tumors, while clearing from most other tissues. PHOTOFRIN does not have any toxic effect on the tumor until it is activated by light from a medical laser and produces a form of oxygen that destroys the cancer.
 PHOTOFRIN was originally discovered by Dr. Thomas Dougherty at Roswell Park Memorial Institute, a leading cancer research center and state-owned facility in Buffalo, N.Y. In return for product rights to PHOTOFRIN, Quadra Logic agreed to provide the state of New York with a 5 percent royalty from the proceeds of PHOTOFRIN sales in oncology.
 American Cyanamid Co. (NYSE: ACY) is QLT's co-development, marketing and distribution partner for cancer and dermatology applications of Photodynamic Therapy.
 Quadra Logic is the world leader in the development of new pharmaceutical products and applications for Photodynamic Therapy. In addition to PHOTOFRIN, the company has initiated clinical trials of its second-generation product, benzoporphyrin derivative, or BPD, as a potential treatment for non-melanoma skin cancer and psoriasis. These trials are ongoing at the British Columbia Cancer Agency in Vancouver and at the Massachusetts General Hospital in Boston.
 -0- 4/20/93
 /EDITOR'S NOTE: A photo accompanying this release is available on the INS Photo Network./
 /CONTACT: David J. Main, director of corporate communications and investor relations of Quadra Logic Technologies, 604-872-7881 or 800-663-5486; or James Hoggan or Sheila Gardner of James Hoggan & Associates, 604-682-5461, for Quadra Logic Technologies/
 (ACY QLT.)


CO: Quadra Logic Technologies Inc.; American Cyanamid Co. ST: British Columbia IN: MTC SU:

BP-JL -- LA017 -- 7830 04/20/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:851
Previous Article:THE FOOTHILL GROUP INC. REPORTS FIRST QUARTER RESULTS
Next Article:INSTRUMENTAL ANNOUNCES NASA INSTALLATION OF UNIX PERFORMANCE MONITORING SOFTWARE; COMPANY'S FIRST PRODUCT RAPIDLY GAINING ACCEPTANCE
Topics:


Related Articles
QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA
QUADRA LOGIC BEGINS BOSTON CLINICAL TRIAL OF NEW DRUG AS A POTENTIAL TREATMENT FOR PSORIASIS
QUADRA LOGIC TECHNOLOGIES INC. ANNOUNCES RESULTS OF TESTS
QUADRA LOGIC TECHNOLOGIES INC. COMPLETES CDN $21.2 MILLION STOCK OFFERING
QLT RECEIVES FIRST EUROPEAN APPROVAL FOR PHOTOFRIN(R); HOLLAND APPROVAL EXPANDS USE TO LUNG AND ESOPHAGEAL CANCERS
QUADRA LOGIC RECEIVES JAPANESE APPROVAL FOR PHOTOFRIN(R)
QUADRA LOGIC RECEIVES JAPANESE APPROVAL FOR PHOTOFRIN(R)
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF PHOTOFRIN(R)
LIGAND TO MARKET AND SELL QLT's PHOTOFRIN(R) IN CANADA
LIGAND LAUNCHES SECOND PRODUCT - PHOTOFRIN(R) IN CANADA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters